Most commercially available biomaterials are versions of commodity materials that were developed for other purposes.

While tremendous advances have been made in these approaches, advances in the more challenging applications of

tissue engineering and regenerative medicine cannot be made without considering different design principles –namely biological design principles.

Our entire materials concept is centered around such biological design principles: how to make materials display biological information

(such growth factors), how to make materials respond to biological signals (such as increases in enzyme activity), and how to deliver

the right signals at the right time to directly control cell behavior.

Such materials are just beginning to appear on the horizon in academic research; our objective is to innovatively carry these

forward to translatable practice.

1- design of new materials

2- liaison with biological teams for generation of combination (material+factor) biomaterial

3- partnering with tissue focused teams to perform evaluation of biomaterial in stimulating tissue

    regeneration including state of the art imaging

4- feedback of information from tissue teams to materials teams for optimisation of biomaterial

5- reverse engineering by companies and clinical specialists to ensure applicability of new biomaterials

6-evaluation by large pharma for further development

In the research and development of biomaterials this strategy represents the optimal approach:

a) We will leverage the pre-investments already made in expertise, infrastructure and resources present within the partnership (amounting to over

    500 million euros) which are now aligned

b) The partnership represents the best teams with proven track record in innovating in this field

c) The constant feedback of applicability into the design and validation process will mean that only those with the highest potential will

    be fast tracked into later stage development

d) Drug development costs between 850million and 1.7billion euros from concept to the clinic. The preinvestments have already been

    made to address the early stage conceptual design, however the costs of clinical validation and market release, which academia does

    not have sufficient resources for, necessitates that there is active partnership with industry who are critical partners to ensure that

    citizens benefit from the work.